Journal article
Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial
Abstract
BACKGROUND: The inhaled corticosteroid fluticasone furoate (FF) in combination with the long-acting β2 agonist vilanterol (VI) is in development for asthma and chronic obstructive pulmonary disease.
OBJECTIVE: To assess the safety and tolerability of FF/VI over 52 weeks in patients with asthma.
Authors
Busse WW; O'Byrne PM; Bleecker ER; Lötvall J; Woodcock A; Andersen L; Hicks W; Crawford J; Jacques L; Apoux L
Journal
Thorax, Vol. 68, No. 6,
Publisher
BMJ
Publication Date
June 2013
DOI
10.1136/thoraxjnl-2012-202606
ISSN
0040-6376
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Administration, InhalationAdolescentAdrenergic beta-2 Receptor AntagonistsAdultAndrostadienesAsthmaBenzyl AlcoholsChildChlorobenzenesDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationDrug ToleranceFemaleFollow-Up StudiesForced Expiratory VolumeGlucocorticoidsHumansMaleRetrospective StudiesTreatment OutcomeYoung Adult